These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21107661)

  • 41. A computer program for pharmacokinetics based on maximum likelihood estimation using the gamma distribution with a probability density function: comparison with the normal distribution.
    Tanikawa K; Matsumoto Y; Matsuzaki T; Shimizu M; Matsumoto M; Fukuoka M
    Biol Pharm Bull; 2000 Feb; 23(2):235-9. PubMed ID: 10706392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does aging need its own program, or is the program of development quite sufficient for it? Stationary cell cultures as a tool to search for anti-aging factors.
    Khokhlov AN
    Curr Aging Sci; 2013 Feb; 6(1):14-20. PubMed ID: 23387885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrated functions for four basic models of indirect pharmacodynamic response.
    Krzyzanski W; Jusko WJ
    J Pharm Sci; 1998 Jan; 87(1):67-72. PubMed ID: 9452970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Recirculatory Model for Pharmacokinetics and the Effects on Bispectral Index After Intravenous Infusion of the Sedative and Anesthetic AZD3043 in Healthy Volunteers.
    Björnsson MA; Norberg Å; Kalman S; Simonsson USH
    Anesth Analg; 2015 Oct; 121(4):904-913. PubMed ID: 26097984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of baseline parameters in determining indirect pharmacodynamic responses.
    Sun YN; Jusko WJ
    J Pharm Sci; 1999 Oct; 88(10):987-90. PubMed ID: 10514344
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of target-mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
    Wang Z; Zeng Z; Ye L; Zhu X; Pei Y; Wang Y; Zheng L
    Br J Clin Pharmacol; 2022 May; 88(5):2084-2095. PubMed ID: 34705278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.
    Budha NR; Kovar A; Meibohm B
    AAPS J; 2011 Dec; 13(4):650-61. PubMed ID: 22005901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling.
    Ando H; Izawa S; Hori W; Nakagawa I
    Theor Biol Med Model; 2008 Aug; 5():19. PubMed ID: 18687151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics.
    Gabrielsson J; Andersson K; Tobin G; Ingvast-Larsson C; Jirstrand M
    Comput Methods Programs Biomed; 2014 Mar; 113(3):815-29. PubMed ID: 24461798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of dosage regimen in controlling indirect pharmacodynamic responses.
    Gobburu JV; Jusko WJ
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):45-57. PubMed ID: 11259832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cell aging in vivo and in vitro.
    Rubin H
    Mech Ageing Dev; 1997 Oct; 98(1):1-35. PubMed ID: 9255755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p16(INK4a) suppression by glucose restriction contributes to human cellular lifespan extension through SIRT1-mediated epigenetic and genetic mechanisms.
    Li Y; Tollefsbol TO
    PLoS One; 2011 Feb; 6(2):e17421. PubMed ID: 21390332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.
    Pérez-Ruixo JJ; Krzyzanski W; Hing J
    Clin Pharmacokinet; 2008; 47(6):399-415. PubMed ID: 18479174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of four basic models of indirect pharmacodynamic responses.
    Dayneka NL; Garg V; Jusko WJ
    J Pharmacokinet Biopharm; 1993 Aug; 21(4):457-78. PubMed ID: 8133465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts.
    Kalampokis A; Argyrakis P; Macheras P
    Pharm Res; 1999 Nov; 16(11):1764-9. PubMed ID: 10571284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extended transit compartment model to describe tumor delay using Coxian distribution.
    Byun JH; Yoon IS; Lee SY; Cho HJ; Jung IH
    Sci Rep; 2022 Jun; 12(1):10086. PubMed ID: 35710563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacodynamic Age Structured Population Model For Cell Trafficking.
    Krzyzanski W; Bauer R
    J Pharm Sci; 2024 Jan; 113(1):257-267. PubMed ID: 37926235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of performance of distributed delay model for chemotherapy-induced myelosuppression.
    Krzyzanski W; Hu S; Dunlavey M
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):329-337. PubMed ID: 29435950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.